Vaccines work by exposing the immune system to antigenic information in a controlled way so that adaptive immune responses develop before or around the time a person encounters the corresponding infectious agent. Depending on the vaccine platform, this information may be supplied as an attenuated organism, an inactivated organism, a purified protein or polysaccharide, a toxoid, a viral vector or genetic instructions such as messenger RNA. Cells process the vaccine material and present antigenic information to lymphocytes.
B cells and T cells that can recognise relevant antigen are activated when appropriate additional signals are present. These cells multiply and differentiate, producing effector mechanisms such as antibodies and cellular immune responses. Some activated cells become memory cells or long lived plasma cells, enabling subsequent responses to be faster, larger or more effective.
Different vaccine platforms use different biological mechanisms to deliver antigen. Live attenuated vaccines contain weakened forms of pathogens that can usually replicate to a limited extent and mimic aspects of natural infection. Inactivated vaccines contain organisms that cannot replicate. Subunit vaccines provide selected molecular components, reducing exposure to unnecessary parts of the pathogen. Conjugate vaccines chemically link polysaccharide antigens to carrier proteins so that the immune system can generate stronger T cell dependent responses, particularly in young children. Toxoid vaccines present inactivated bacterial toxins so that antibodies can neutralise the toxin. Viral vector vaccines use a modified carrier virus to deliver genetic information, while messenger RNA vaccines provide temporary instructions for cells to make a selected antigen.
After vaccination, innate immune mechanisms help determine the character of the adaptive response. Cells detect vaccine components and associated molecular signals through innate immune receptors. Antigen presenting cells such as dendritic cells can take up material, process it and display peptide fragments on major histocompatibility complex molecules. They then migrate or interact with lymphocytes in lymphoid tissues.
Effective T cell activation requires more than recognition of an antigenic peptide because additional costimulatory and cytokine signals help determine whether the T cell becomes activated and what functional type it develops into. This connection between innate sensing and adaptive specificity is one reason vaccine formulation matters. Adjuvants in some vaccines are specifically designed to enhance appropriate innate immune activation and thereby improve adaptive responses to the vaccine antigen.
B cells are central to many vaccine responses because they can develop into plasma cells that produce antibodies. Antibodies can neutralise viruses and toxins, prevent microbial attachment, promote phagocytosis and activate complement, depending on their class and target. In lymphoid tissues, activated B cells can participate in germinal centre reactions involving proliferation, somatic hypermutation and affinity selection. These processes can produce antibodies with improved binding characteristics.
Class switch recombination can change the antibody class and therefore its functional interactions while retaining recognition of the relevant antigen. Long lived plasma cells can maintain antibody production after vaccination, while memory B cells remain available for later responses. The resulting antibody repertoire is one of the major mechanisms through which many vaccines protect against infection or disease.
T cells contribute differently depending on the vaccine and pathogen. Helper T cells provide signals that support B cell responses and coordinate immune activity. Cytotoxic T cells can recognise pathogen derived peptides displayed by infected cells and destroy those cells, limiting intracellular replication. Some vaccines generate strong cellular immunity, which can be particularly important for pathogens that replicate inside host cells. Memory T cells can persist after the initial response and respond rapidly during subsequent exposure. The balance between antibody mediated and cellular immunity depends on antigen form, delivery route, adjuvantation, vaccine platform and pathogen biology. A vaccine therefore should not be understood as simply producing antibodies. Its effects can involve several arms of the adaptive immune system operating together.
Booster vaccination can reinforce and reshape existing immune memory. A subsequent dose may increase antibody concentrations, promote additional affinity maturation, expand memory B cells and strengthen T cell responses. The need for boosters varies because immune memory and antibody levels have different durations for different vaccines and diseases. Pathogens can also evolve, producing antigenic changes that reduce recognition by existing antibodies. Updated vaccines can therefore be formulated to represent more recent or strategically selected antigenic variants.
The immune system's response to a booster is generally not identical to the primary response because memory cells are already present. This is an important reason why vaccination schedules are designed from experimental and clinical evidence rather than assuming that one exposure always produces permanent protection.
Vaccine protection can be measured using several different outcomes. Immunogenicity refers to the ability of a vaccine to generate an immune response, whereas effectiveness refers to performance under real world conditions and efficacy generally refers to performance under specified study conditions. Surrogate measures such as antibody titres can be useful, but an antibody concentration does not always perfectly predict protection because cellular immunity, antibody quality, tissue localisation and other mechanisms can contribute.
Clinical trials and observational studies can assess outcomes such as infection, symptomatic disease, hospitalisation or death depending on the research question. Vaccine performance can vary with age, immune status, pathogen strain, time since vaccination, exposure intensity and prior immunity. These distinctions prevent the mistaken assumption that one laboratory measurement completely describes vaccine protection.
Vaccines differ from antibiotics and antiviral medicines in their primary purpose and timing. Antibiotics target susceptible bacteria after or during infection, while vaccines aim to prepare immune defences in advance. Antiviral medicines directly interfere with specific stages of viral replication or other viral processes, whereas vaccines train immune recognition.
Vaccination also differs from passive antibody treatment because a vaccine stimulates the individual's own immune system to develop active immunity, while passive antibody administration supplies ready made antibodies and generally provides temporary protection. The overall principle of vaccination is therefore anticipatory immune preparation. By introducing selected antigenic information in a controlled form, vaccines allow the immune system to undergo the cellular selection, expansion and memory formation needed to respond more efficiently when genuine pathogen exposure occurs.
